

# Use of crystalline glucosamine sulfate in osteoarthritis

Gabriel Herrero-Beaumont<sup>†</sup>

& Lucio C Rovati

<sup>†</sup>Author for correspondence  
Autonomous University of Madrid, Rheumatology Department, Fundación Jiménez Díaz-Capio, Avenida Reyes Católicos 2, 28040 Madrid, Spain  
Tel.: +34 915 504 918;  
Fax: +34 915 494 764;  
gherrero@fjd.es

The pharmacological treatment of osteoarthritis is traditionally accomplished with nonspecific symptomatic agents, which are generally effective only for acute symptom relief. Compounds are under investigation that might exert specific effects on osteoarthritis pathogenesis and thus induce at least a similar short-term symptomatic effect, but also control disease progression in the long term. Glucosamine sulfate reverses the proinflammatory and joint-degenerating effects of interleukin-1 by inhibiting the cytokine intracellular signaling pathway. Clinical trials with the crystalline glucosamine sulfate formulation approved as a prescription drug, predominantly at the dose of 1500 mg once daily, demonstrated a specific symptom-modifying effect over short- and long-term treatment courses. Two 3-year trials suggested that the drug also has joint structure-modifying properties and, therefore, might be useful as a disease-modifying agent in osteoarthritis. However, efficacy data obtained with this prescription glucosamine sulfate formulation may not be applicable to all glucosamine products that are available as dietary supplements.

Osteoarthritis is the most common form of arthritis and the most prevalent among rheumatic diseases. It is a degenerative joint disorder with minimal signs of inflammation, which may affect all diarthrodial joints and whose most appropriate definition combines a description of the pathology of the disease with pain that occurs with joint use [1]. Osteoarthritis is particularly frequent at the large, weight-bearing joints of the lower limbs. Radiographic osteoarthritic changes of the knee tibiofemoral compartment occur in 5–15% of the general population aged 35–74 years in the Western world [2]. Symptomatic knee disease occurs in approximately 6% of US adults over 30 years of age [3], with general incidence and prevalence increasing two- to tenfold from age 30 to 65 years [4]. The impact on disability attributable to knee osteoarthritis is similar to that due to cardiovascular disease and greater than that caused by any other medical condition in the elderly [5].

Treatment guidelines for knee and hip osteoarthritis have been developed by both the American College of Rheumatology (ACR) [6] and the European League Against Rheumatism (EULAR) [7,8]. The two guidance documents have been developed by different procedures and, although they share some basic principles, differ with respect to the level of recommendation of specific classes of drugs. This is particularly evident for SYmptomatic Slow Acting Drugs in OsteoArthritis (SYSADOA), the class of agents in which the drug focussed on in this review is generally included, and might be due to

the differences in the regulatory status between the USA and Europe. For this and other reasons, the guidelines may soon need further updates.

Both guidelines suggest that acetaminophen (paracetamol) should be the oral analgesic used initially and, if successful, the preferred long-term symptomatic agent [6–8]. Nevertheless, this pure analgesic is less effective than nonsteroidal anti-inflammatory drugs (NSAIDs) in short-term pain relief [9]. On the contrary, recent meta-analyses suggest that the efficacy of NSAIDs in osteoarthritis is not great and, in particular, their long-term use is not supported by available data [10].

Therefore, there is a need for medications that offer acceptable short-term symptom control, but in particular have a role in the medium- and long-term management of disease (symptom-modifying effect), including the possibility to delay the progression of joint structure changes (structure-modifying effect), thereby affecting the evolution of the disease and thus preventing clinically significant disease outcomes (disease-modifying effect). These aims might be achieved by drugs that, unlike unspecific symptomatic agents, might exert specific effects on osteoarthritis pathogenesis factors. To date, glucosamine sulfate is probably the drug with the most extensive evidence in this regard.

## Glucosamine sulfate

Glucosamine is a naturally occurring monosaccharide and a normal constituent of glycosaminoglycans in the cartilage matrix and

**Keywords:** clinical trials, disease modification, glucosamine sulfate, interleukin-1, joint-space narrowing, osteoarthritis, pharmacokinetics, safety, structure modification, symptom modification

future  
medicine

synovial fluid [11]. However, it also exerts specific pharmacological effects on osteoarthritic cartilage and chondrocytes. Glucosamine base must be salified for pharmaceutical use, and glucosamine sulfate is the salt that was originally developed as a prescription drug and used in the vast majority of osteoarthritis clinical trials. However, some recent generic over-the-counter products and in particular a number of dietary supplements may contain glucosamine hydrochloride, whose treatment effects are much less well characterized, as will be discussed. In addition, several dietary supplements have appeared that claim glucosamine sulfate content, but that may be different from the prescription product described below.

For these reasons, the present review will concentrate on the crystalline glucosamine sulfate formulation that has been approved as a prescription drug in Europe and elsewhere, and that is available as a branded dietary supplement in the USA. Nevertheless, high-quality clinical trials conducted with glucosamine hydrochloride or other glucosamine sulfate formulations will also be reviewed, and their results analyzed to assess the overall evidence available for the use of glucosamine in osteoarthritis. In this respect, it must be noted that a recent Cochrane Review identified major differences in the results of clinical trials conducted with the glucosamine sulfate prescription formulation described here and those of studies conducted with other glucosamine preparations which failed to demonstrate a similar efficacy [12].

### Chemistry

Crystalline glucosamine sulfate (Dona<sup>®</sup>, Viartil-S<sup>®</sup>, Arthryl<sup>®</sup>, Xicil<sup>®</sup> or other trademarks by the originator company Rottapharm, Monza, Italy), is also known as glucosamine sulfate sodium chloride. It is a pure substance (molecular weight [Mw]: 573.31) synthesized from chitin of sea origin and in which glucosamine (Mw = 179.17), sulfate, chloride and sodium ions are present in stoichiometric ratios of 2:1:2:2 (Figure 1). Glucosamine sulfate (Mw = 456.43) does not appear to be stable, unless prepared as crystalline glucosamine sulfate according to this patented process [13]. The dose is expressed as the net content in glucosamine sulfate and, as a prescription drug, the substance is most widely available as sachets of powder for oral solution of 1500 mg glucosamine sulfate to be administered once daily.


At present, it is unclear how other preparations of glucosamine sulfate, mainly available in countries where the substance is regulated as a dietary

supplement, compare with this prescription formulation in terms of active ingredient content, purity and stability, since this information is generally not available. When formulations are unknown, and especially in view of the absence of appropriate bioequivalence studies (see 'Pharmacokinetics and metabolism' section), it is not known how the clinical efficacy and safety results obtained with crystalline glucosamine sulfate apply to these uncontrolled nutraceutical or generic preparations, and *vice versa*.

### Pharmacodynamics

Glucosamine is preferentially incorporated by chondrocytes into the components of glycosaminoglycan chains in intact cartilage [14]. It stimulates the synthesis of physiological proteoglycans [15–17] and decreases the activity of catabolic enzymes in the cartilage, including matrix metalloproteases (MMPs) [17,18]. The compound is effective *in vivo* in experimental animal models of osteoarthritis [19,20]. For several years, the dominant belief was that most of the activities and the mechanism of action of glucosamine sulfate might be reconducted to the mere incorporation of glucosamine in glycosaminoglycans and, thus, the stimulation of their synthesis as a simple building block. However, this hypothesis appears to be over-simplified. In fact, while metabolic effects, especially if exerted at the level of the articular cartilage, might support a long-term joint structure-modifying activity, they may hardly explain the relatively short-term symptom-modifying effects outlined in clinical trials. Unsurprisingly, recent studies have demonstrated that glucosamine concentrations that are able to stimulate glycosaminoglycans synthesis *in vitro* are high [21] and probably largely in excess of those that may be achieved in biological fluids after oral administration to humans [22].

On the other hand, selected *in vitro* models illustrated that glucosamine might be metabolically effective at concentrations 100-fold lower and compatible with those found in biological fluids during treatment in humans [17]. In addition, the compound may selectively cumulate in the cartilage after repeated dosing, thereby possibly providing higher local concentrations [23]. An alternative hypothesis has been proposed that suggests looking for glucosamine metabolic activities in tissues where extracellular glucosamine concentrations should be higher, including the intestine, liver and kidney, and might modulate the compound anti-arthritic effects [24]. However, this hypothesis appears to be premature at present.

**Figure 1. Crystalline glucosamine sulfate.**

A unifying hypothesis for the compound mechanism of action in osteoarthritis has recently been proposed and supports the role of glucosamine sulfate as both a symptom- and structure-modifying agent in osteoarthritis. This mechanism refers to glucosamine-induced reversal of the pro-inflammatory and joint-degenerating effects of interleukin (IL)-1 [18,25,26]. More specifically, it inhibits the cytokine intracellular signaling cascade, namely the activation of the nuclear factor (NF)- $\kappa$ B pathway [27]. In particular, glucosamine sulfate has been shown to inhibit the IL-1-induced activation and nuclear translocation of active NF- $\kappa$ B family members in human osteoarthritic chondrocytes [28]. Via this mechanism, glucosamine sulfate was able to inhibit the gene expression and protein synthesis of cyclooxygenase (COX)-2, selectively over COX-1, thereby preventing the release of prostaglandin (PG) $E_2$  in the culture media [28].

Several new evidences are progressively appearing to further substantiate this mechanism of inhibiting IL-1-induced expression of genes involved in the pathophysiology of joint inflammation and tissue destruction. NF- $\kappa$ B activity is inhibited by glucosamine sulfate at the level of both chondrocytes and synoviocytes, with a concomitant decrease in COX-2 protein synthesis, PGE $_2$  release and, in chondrocytes, nitric oxide release, with a pattern that differs from that of other potential anti-osteoarthritic agents and NSAIDs [29]. Moreover, glucosamine sulfate consistently decreased IL-1-induced MMP synthesis in both type of cells, while NSAIDs tended to further increase their production [29].

Most of these *in vitro* experiments used glucosamine concentrations that were higher than those found in human plasma after therapeutic doses (see 'Pharmacokinetics and metabolism'), which is common in mechanistic studies. However, recent studies indicated that this

mechanism is operative at glucosamine concentrations of approximately 10  $\mu$ M or lower [30], specifically, the concentrations found in human plasma or synovial fluid after therapeutic doses of crystalline glucosamine sulfate. Effective glucosamine concentrations (expressed as IC $_{50}$ ) that inhibit IL-1-stimulated gene expression of different pro-inflammatory or prodegenerative transcripts have been reported to range between 6.2 and 13.8  $\mu$ M for IL-1 itself, MMP-3, COX-2 and inducible nitric oxide synthase [30].

Another recent study confirmed that, *in vitro*, glucosamine inhibits gene expression in the osteoarthritic cartilage [31]. Since glucosamine inhibits both anabolic and catabolic genes, the authors speculate that the therapeutic effects as a potential disease-modifying agent might be due to anticatabolic activities, rather than anabolic activities. Interestingly, they also found that glucosamine sulfate is a stronger inhibitor of gene expression than glucosamine hydrochloride [31], which may help to explain the different findings of recent clinical trials with different glucosamine salts and formulations, along with the recent human pharmacokinetic findings.

The differences between glucosamine sulfate and glucosamine hydrochloride might be important at both the pharmacological and pharmacokinetic levels, with sulfate concentrations increasing after administration of glucosamine sulfate [32,33]. This might possibly overcome a deficiency in inorganic sulfur caused by low levels of dietary proteins (containing sulfur amino acids) in the elderly. Sufficient sulfur is essential for the synthesis of proteoglycans and other sulfur-containing metabolic intermediates (e.g., coenzyme A and glutathione) that are important for chondrocyte metabolism [32,33].

#### Pharmacokinetics & metabolism

For a long period, limited knowledge about glucosamine pharmacokinetics (including oral bioavailability, peak plasma levels and tissue distribution) hampered the full understanding of the relationships between the compound clinical effects and its mechanism of action. In addition, the inability to document the compound pharmacokinetics and, thus, to perform bioequivalence studies against the patented formulation of crystalline glucosamine sulfate approved as a prescription drug in continental Europe and elsewhere, favored the appearance on the market of other undocumented glucosamine salts (e.g., hydrochloride), improperly stabilized glucosamine

sulfate substances, different dosage forms or regimens, whose clinical trial results were clearly less favorable (as will be reviewed later).

The main limitation for the description of glucosamine pharmacokinetics has been the lack of suitable bioanalytical methods with sufficient sensitivity and specificity for the detection of the compound in biological fluids. Early studies tried to elucidate the pharmacokinetics and metabolism of oral glucosamine sulfate in rats, dogs and humans, using  $^{14}\text{C}$ -labeled glucosamine [23]. Although these studies provided compelling information about the absorption, distribution and elimination of radioactivity, they were not fully able to differentiate the unchanged drug from its metabolites and/or degradation products. When tentative specific methods for the determination of glucosamine in human plasma were developed, they were not suitably sensitive to monitor the plasma concentrations of the unchanged compound after oral administration of therapeutic doses [23].

More recent investigations into different forms of oral glucosamine in rats [34], dogs [35] and horses [36] had to use doses much higher than those used therapeutically in humans owing to the high limit of quantization of the assays employed, and their relevance to the treatment of osteoarthritis is at least questionable. Nevertheless, the serum and synovial fluid concentrations of glucosamine have been determined in horses with reasonable assay sensitivity, after single-dose administration of glucosamine hydrochloride at what the authors designated 'human clinically relevant' doses, although they failed to use an allometric scale to calculate such doses and, therefore, their results are difficult to interpret [24]. Nevertheless, maximal glucosamine concentrations in plasma were similar to those later described in humans [22,37]. Conversely, the concentrations in the synovial fluid were at least tenfold lower [24].

A very preliminary study in patients with variously localized osteoarthritis found glucosamine plasma levels up to  $11.5\ \mu\text{M}$ , 1.5–3 h after ingestion of a single 1500 mg dose of glucosamine sulfate. Although these peak plasma levels were in line with those found in correct human pharmacokinetics studies [36], they were not reached in all patients, possibly due to protocol limitations, as acknowledged by the authors themselves [22].

The complete pharmacokinetic profile of glucosamine has lately been described by Persiani and colleagues, after repeated administrations

(i.e., at steady state) of the standard crystalline glucosamine sulfate formulation, (1500 mg once daily), to healthy volunteers in a rigorously designed pharmacokinetics study [37]. These authors have developed and validated a liquid chromatography method with mass spectrometry detection (LC-MS/MS) that has a very low limit of quantitation [37]. This enabled them to detect endogenous plasma glucosamine concentrations with distinct intrasubject variability, and to study the pharmacokinetics of the exogenously administered compound with higher precision. They found that glucosamine is rapidly bioavailable from orally administered crystalline glucosamine sulfate, with maximum average plasma concentrations up to 100-fold higher than endogenous levels and in the  $10\ \mu\text{M}$  range after approximately 3 h. Steady-state pharmacokinetics parameters indicate that glucosamine distributes to both the vascular and extravascular compartments and is eliminated with a half-life estimated to be approximately 15 h, thus supporting once-daily dosing. Absolute bioavailability could not be assessed in this study, but was estimated to be approximately 25% with the help of other recent animal data [38].

Preliminary knee osteoarthritis patient data from the same group indicate the presence of endogenous glucosamine levels in both plasma and synovial fluid, with distinct intrasubject variability (particularly at the level of the latter), whose possible pathophysiological significance should be further investigated [39]. In these patients, repeated once-daily doses of 1500 mg crystalline glucosamine sulfate reached similar peak plasma and synovial fluid concentrations, with an almost 1:1 relationship, which were also in the  $10\ \mu\text{M}$  range [39]. These data are different from those described in horses [24] and call attention to possible species-specific differences and/or on the precision of the assays employed, which appears to be higher in the studies by Persiani and colleagues [37,39]. Interestingly, the  $10\ \mu\text{M}$  concentration range found in human plasma and synovial fluid [21,37,39] is effective on chondrocytes *in vitro* in the inhibition of IL-1-induced gene expression [30]; specifically, the putative mechanism of action of glucosamine in osteoarthritis. Conversely, the same concentrations are probably insufficient to stimulate cartilage glycosaminoglycan synthesis [21,22]. This finding would suggest abandoning this latter over-simplified hypothesis.

Single-dose pharmacokinetic studies with other glucosamine formulations at the same unit dose of 1500 mg, such as the glucosamine hydrochloride solid preparation used in the Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) (see later), found glucosamine peak concentrations in plasma that were only 3  $\mu\text{M}$  [40], that is, at least threefold lower than the steady-state concentrations reached with 1500 mg of crystalline glucosamine sulfate, and they might be even lower when the 1500 mg daily dose is fractionated; for example, as 500 mg three-times daily, as in GAIT. These lower concentrations found with glucosamine hydrochloride are less effective *in vitro* on the putative mechanism of action of glucosamine described earlier [30].

Unfortunately, there are no pharmacokinetics and bioavailability studies of other glucosamine sulfate preparations and, therefore, it is impossible to comment on their clinical value relative to the prescription formulation.

#### *Clinical efficacy*

The putative mechanism of action, described above, supports the role of glucosamine sulfate as both a symptom- and structure-modifying drug in osteoarthritis.

All clinical trials performed until the end of 2004 have been systematically evaluated in a recent Cochrane review [12], which supersedes two previous high-quality meta-analyses [41,42]. This Cochrane review considered the results of all 20 eligible randomized controlled trials (RCTs) available at that time with any glucosamine formulation for symptom modification and concluded that glucosamine was superior to placebo for improvement in both pain and function, with a moderate effect size. However, these results were driven by the ten RCTs that evaluated the prescription formulation of crystalline glucosamine sulfate object of this review (labeled ‘Rotta preparation’ in the Cochrane review) and which found a high effect size for pain and a moderate effect size for function relative to placebo. Pooled results for trials using a different glucosamine preparation failed to reach statistical significance when compared with placebo.

Only high-quality trials conducted with any glucosamine formulation will be considered in this review. Given the different results outlined in the Cochrane Review, trials of prescription crystalline glucosamine sulfate are the main subject of this review, and they will be reported separately from studies performed with other formulations.


High-quality trials of crystalline glucosamine sulfate can be classified based on their treatment duration and aims.

Short-term trials of glucosamine sulfate for symptom relief

Besides placebo-controlled trials, four short-term studies compared the prescription glucosamine sulfate formulation with an NSAID, and found it superior in two and equivalent in two, for treatment periods between 4 and 12 weeks [12].

One of the studies that better describes the short-term, symptom-modifying effect of glucosamine sulfate versus both placebo and NSAIDs has been published in abstract form [43]. Based on the complete data and information largely reported below, the Cochrane review established that this study had adequate allocation concealment and the highest rated methodological quality for both study design and analysis [12]. This was a randomized, double-blind, placebo- and active-controlled trial on four parallel groups of patients, with mono- or bilateral primary knee osteoarthritis, according to the ACR criteria. Patients (a total of 319; 75% females) had an average age of 65.5 years, a mean body mass index (BMI) of 27.8, and a history of daily knee pain and function limitation requiring medical treatment for at least the previous 6 months. After wash-out from previous symptomatic medications, they were randomly assigned to once-daily treatment for 12 weeks with either 1500 mg glucosamine sulfate powder for oral solution, one 20 mg piroxicam capsule, the combination of both glucosamine sulfate and the NSAID, or double placebo, according to a double-dummy technique to preserve blindness in all groups. At the end of the 12 weeks, treatments were withdrawn and patients followed-up for a further 8 weeks. Acetaminophen (paracetamol) 500 mg tablets were provided for rescue analgesia as needed, and their use recorded on a patient daily diary. All groups were comparable for demographic and baseline disease characteristics, the latter being of moderate severity. Figure 2 reports the change in the primary parameter represented by the Lequesne index, whose final outcome is reported in Table 1. Both glucosamine sulfate and piroxicam demonstrated a distinct trend for improvement over placebo, evident already after 2 weeks of treatment and similar for the two drugs up to 4 weeks. As listed in Table 1, this behavior was superimposable to that demonstrated in previous 4-week placebo-controlled [44] or NSAID-controlled [45] trials. After

**Figure 2. Mean change in the Lequesne index score (in points, with 95% confidence interval) at each visit compared with treatment period (left), or to end of treatment values for the follow-up (right).**



Patients evaluable at each visit are reported at the bottom of the figure. Baseline values, final differences and statistical analysis for the entire intention-to-treat population are reported in **Table 1**. Symbols reported in this figure represent the intention-to-treat results in the analysis of variance for repeated measures on the curve of the timecourse of effects [43].  
 \*p < 0.001 versus placebo; †p < 0.01 versus piroxicam (treatment period); §p < 0.05 versus placebo; ¶p < 0.05 versus piroxicam (follow-up period).

4 weeks, the improvement with glucosamine sulfate continued slightly more steadily than with piroxicam (Figure 2, left) and was superior at the end of the 12-week treatment course. The combination of glucosamine sulfate with the NSAID tended to exhibit an insignificant faster symptomatic effect over the first 15 days of treatment. Thereafter, the improvement was indistinguishable from that of glucosamine sulfate alone. Over the 8 weeks of follow-up after drug withdrawal, the patients previously receiving piroxicam tended to lose most of the effect formerly achieved (Figure 2, right and Table 1). Conversely, the previous beneficial effect was long-lasting in patients who had received glucosamine sulfate alone or in combination with the NSAID. Recourse to paracetamol for rescue analgesia in this trial was occasional and variable, with minimal average consumption (<1–2 tablets/day) in a similar proportion of patients, without significant differences between groups.

Long-term trials for disease modification & new trials for the management of disease symptoms  
 Glucosamine sulfate should not be regarded as a drug for short-term symptom relief, but one for osteoarthritis disease management. This includes symptom modification over appropriate treatment durations, specifically at least 6 months according to current regulatory guidelines [46], and possibly long-term trials for both joint structure modification and symptom modification (i.e., true disease modification). Three pivotal trials currently satisfy these requirements for crystalline glucosamine sulfate.

Reginster and colleagues [47] and Pavelka and colleagues [48] were the first to demonstrate a putative disease-modifying effect by a pharmacological agent in two long-term studies. In these 3-year, randomized, placebo-controlled clinical trials, they were able to demonstrate that glucosamine sulfate was not only able to control the symptoms of the disease over such a

**Table 1. Mean change in the Lequesne algo-functional index from baseline in crystalline glucosamine sulfate high-quality trials of different treatment durations.**

	Noack [44]		Rovati [43]		Herrero-Beaumont [58]			Pavelka [48]				
	Placebo n = 120	GS n = 121	Placebo n = 77	GS n = 79	Piroxicam n = 86	Combination* n = 77	Placebo n = 104	GS n = 106	Acetaminophen n = 108	Placebo n = 101	GS n = 101	
Baseline	10.6 ± 3.5	10.6 ± 3.6	10.4 ± 3.0	10.3 ± 3.0	10.8 ± 3.0	11.1 ± 3.3	10.8 ± 2.6	11.0 ± 3.1	11.1 ± 2.7	8.9 ± 2.3	9.0 ± 2.3	
<b>Change from baseline</b>												
4 weeks	-2.3 (-2.9 to -1.7)	-3.2 (-3.9 to -2.6) p = 0.037 vs placebo	-0.7 (-1.4 to -0.1)	-4.8 (-5.4 to -4.2) p < 0.001 vs placebo p < 0.001 vs piroxicam NS vs combination	-2.9 (-3.5 to -2.2) p < 0.001 vs placebo p = 0.003 vs combination	-4.5 (-5.2 to -3.7) p < 0.001 vs placebo	-1.9 (-2.6 to -1.2)	-3.1 (-3.8 to -2.3) p = 0.032 vs placebo	-2.7 (-3.3 to -2.1) NS vs placebo	-0.8 (-1.1 to -0.5)	-1.7 (-2.2 to -1.2) p = 0.002 vs placebo	
12 weeks												
6 months												
3 years												
<b>Change from end of treatment</b>												
8 weeks	0.2 (-0.6 to 1.1)	0.4 (-0.1 to 0.9) NS vs placebo p = 0.02 vs piroxicam NS vs combination	0.2 (-0.6 to 1.1)	0.4 (-0.1 to 0.9) NS vs placebo p = 0.02 vs piroxicam NS vs combination	1.8 (1.2 to 2.4) p = 0.01 vs placebo	0.6 (-0.1 to 1.3)	0.2 (-0.6 to 1.1)	0.4 (-0.1 to 0.9) NS vs placebo p = 0.02 vs piroxicam NS vs combination	1.8 (1.2 to 2.4) p = 0.01 vs placebo	0.6 (-0.1 to 1.3)	0.2 (-0.6 to 1.1)	0.4 (-0.1 to 0.9) NS vs placebo p = 0.02 vs piroxicam NS vs combination

*Intention-to-treat (ITT) approach by the last observation carried forward, except in Pavelka [48] where a worst-case scenario was employed. The lower row reports the mean change from the end of treatment scores, after drug withdrawal, in the only study where this assessment was performed (see also Figure 2), with an ITT approach on all treatment period completers, assuming return to baseline values for early withdrawals. Statistical analysis by analysis of variance, with correction for multiple comparisons by Dunnett pairwise comparisons in Herrero-Beaumont [58], or by the Tukey test, after covariating on baseline and end-of-treatment scores, respectively, in Rovati [43]. Two high-quality trials could not be included in this table: the study by Müller-Fassbender [45] versus ibuprofen for using a modified version of the Lequesne index and whose results for GS at 4 weeks are superimposable to those of Noack [44] and not different from those obtained for ibuprofen 1200 mg/day; the long-term placebo-controlled study by Reginster [47] for using the WOMAC index only and whose results at 3 years are superimposable to those of Pavelka [48] who used the WOMAC index as a secondary end point.*

Data are mean ± SD for baseline scores and mean with 95% confidence interval for changes.

\*Combination of glucosamine sulfate + piroxicam.

GS: Glucosamine sulfate; NS: Not significant; SD: Standard deviation; WOMAC: Western Ontario and Macmaster osteoarthritis index.

long-term treatment course, but could also significantly decrease the progression of joint structure changes in patients with mild-to-moderate osteoarthritis of the knee. The data were particularly strong in the subgroup of female postmenopausal patients [49].

Joint structure changes were principally assessed by monitoring radiographic joint space narrowing. The results are summarized in Table 2 and illustrate a similar quantitative effect in the two trials, as previously acknowledged [42]. Reservations have been expressed that these results were obtained with the full extension knee radiographic view, a technique that, although state-of-the-art at the time of the trials, might be less efficient than newer semiflexed views, and the results might have been biased by the marked symptom improvement by glucosamine sulfate [48]. In fact, improvement in pain might improve the degree of knee extension and artifactually increase the tibiofemoral joint radiographic space, by changing the medial tibial plateau alignment with the x-ray beam [50]. However, it has recently been demonstrated that pain was not a confounder in joint space narrowing assessment in these trials [51].

Indeed, the long-term symptom-modifying effect in the two long-term trials was termed ‘impressive’ [52]. Other reports have questioned the significance of this symptom improvement [53]; however, this has been recently reassessed and found to be clinically relevant [54], although the effect size is small due to the mild symptom characteristics of the patients at enrolment.

In addition, preliminary follow-up data of these patient cohorts suggest that, on average, 5 years after the end of the two long-term trials and drug withdrawal, the patients who had received glucosamine sulfate were less likely to undergo total joint replacement [55,56]. If confirmed, these data would indicate that glucosamine sulfate might indeed affect the progression of osteoarthritis,

preventing clinically significant disease outcomes. This finding might be explained by the symptom- and structure-modifying effect achieved during the treatment period, in terms of clinically relevant response. In particular, a recent position paper suggested that ‘failure’ to treatment might be a good predictor of joint surgery and a proper surrogate outcome during long-term clinical trials for disease modification in osteoarthritis [57]. When this group of experts assessed the proportion of ‘failures’, defined as a joint space narrowing of at least 0.5 mm, and less than 20% improvement in the Western Ontario and MacMaster OA Index (WOMAC) pain subscale, in the two long-term studies by Reginster and colleagues and by Pavelka and colleagues, they found that there were 41% failures overall with glucosamine sulfate versus 60% on placebo ( $p = 0.003$ ) [57].

The most recent pivotal study assessed the role of glucosamine sulfate in the management of knee osteoarthritis symptoms over 6 months in comparison with placebo and with a reference drug represented by acetaminophen (paracetamol) [58]; in other words, the preferred long-term symptomatic medication indicated by current osteoarthritis practice guidelines [6,7]. The Glucosamine Unum In Die (once-a-day) Efficacy (GUIDE) trial evaluated 318 patients (88% women) randomized to double-dummy placebo, or 1 g acetaminophen tablets three-times daily, or to the standard prescription formulation of glucosamine sulfate soluble powder 1500 mg once daily (hence the acronym of the study). The data reported in Table 1 illustrate that the mean improvement in the Lequesne index with glucosamine sulfate was significantly higher than with placebo. Conversely, the improvement with acetaminophen failed to reach statistical significance versus placebo. The clinical relevance of the effect size of glucosamine sulfate on the primary outcome in

**Table 2. Radiographic joint space width (mean ± SD) and 3-year JSN at the narrowest point of the medial tibio-femoral compartment of the knee joint, as reported by Reginster [47] and Pavelka [48].**

Study (sample size)	Enrolment JSW		3-year JSN		Ref.
	Placebo	GS (mean ± SD; mm)	Placebo	GS (mean ± 95% CI; mm)	
Reginster (n = 106,106)	3.95 ± 1.24	3.82 ± 1.32	-0.40 (-0.56 to -0.24)	-0.07* (-0.22 to 0.07)	[47]
Pavelka (n = 101,101)	3.63 ± 1.57	3.89 ± 1.48	-0.19 (-0.29 to -0.09)	-0.04 <sup>‡</sup> (-0.06 to 0.14)	[48]

\* $p = 0.003$  and <sup>‡</sup> $p = 0.001$  versus placebo.

CI: Confidence interval; GS: Glucosamine sulfate; JSW: Joint space width; JSN: Joint space narrowing; SD: Standard deviation.



this trial is witnessed by the higher proportion of treatment responders according to the Osteoarthritis Research Society (OARSI-A) criteria: 39.6 versus 21.2% with placebo ( $p = 0.007$ ). Acetaminophen also had more responders than placebo, although at a lower degree of significance (33.3%;  $p = 0.047$ ).

These results suggest that glucosamine sulfate might be the preferred symptomatic medication in knee osteoarthritis *vis a vis* current practice guidelines, if employed at the standard dose regimen of the prescription formulation of this and the previously described pivotal trials. On the other hand, these results are at odds with those of the National Institutes of Health (NIH)-supported GAIT study, where the glucosamine-treated group demonstrated only a nonsignificant trend of efficacy [59]. This large, 6-month trial compared glucosamine, given as dietary supplement glucosamine hydrochloride 500 mg three-times daily or chondroitin sulfate, or their combination, with placebo and with celecoxib as a reference standard. The overall results might be clouded by the huge placebo effect (60%), and by an insufficiently controlled use of the rescue analgesic medication, since even the reference standard medication produced disappointing, although statistically significant, efficacy results compared with placebo [60]. Conversely, none of the supplements was significantly superior to placebo [59]. Glucosamine hydrochloride at the dose of 500 mg three-times daily was used only in one previous RCT whose results were mostly negative [61]. Indeed, the editorial accompanying the GAIT study states that the NIH finding for glucosamine is not surprising, given the non-conventional glucosamine formulation used, since all previous favorable trials have been conducted with the glucosamine sulfate prescription preparation [62]. As described in the ‘Pharmacodynamics’ and ‘Pharmacokinetics’ sections earlier, the peak glucosamine plasma levels achieved with the NIH hydrochloride formulation are much lower [40] than with the prescription sulfate formulation used in GUIDE [37,39] and, therefore, they might not share the same pharmacological properties [30]. In addition, sulfates have been suggested as an important component of the glucosamine mechanism of action [32]. Interestingly, the most significant results in GAIT were achieved in a subgroup analysis in more severe patients when glucosamine hydrochloride was combined with chondroitin sulfate [59], presumably increasing the sulfate plasma levels [33], if not even those of

glucosamine metabolites, to concentrations closer to those achieved with the prescription glucosamine sulfate formulation used in GUIDE and the other pivotal trials.

Overall assessment of the symptom-modifying effect of crystalline glucosamine sulfate in both short- & long-term clinical trials

Table 1 demonstrates a coherence of results for symptomatic improvement with glucosamine sulfate over short-to-medium-term treatment courses ranging from 4 weeks to 6 months [43–45,58]. The magnitude of the effect also appears to be comparable, with the exception of one trial where it is higher mainly due to a lower placebo response [43].

In the trials where a comparison with a non-specific symptomatic medication is performed, glucosamine sulfate might provide similar symptom relief after the first 2–4 weeks [43,45] and it might lean towards superiority in studies of 3–6 months duration [43,58], including a persistent effect after drug withdrawal, compared with a progressive loss of effect, for example, with NSAIDs [43].

In the long-term trial by Pavelka that used the Lequesne index as the primary symptom outcome, the effect size relative to placebo on this parameter is similar to that observed in shorter trials [48], as suggested by the data in Table 1 and as acknowledged by the Cochrane review [12].

Few published trials of crystalline sulfate used the WOMAC index as a symptom outcome (i.e., only the long-term trials of Reginster [47] and Pavelka [48]), and reported a significant difference on the total index and on both pain and function subscales. While the difference on the total index is clearly clinically relevant, the Cochrane review indicates that the standardized mean difference for WOMAC pain and function is not significant, suggesting an effect size that might not be clinically relevant [12]. However, when the effect size is calculated according to the standard formula (Table 3), it is statistically significant for both parameters in both trials, again with a coherence of results between the two. The effect size is small (i.e., between 0.20 and 0.50), but this is not surprising in long-term, 3-year, placebo-controlled trials in patients with mild disease characteristics. In addition, this effect size is of the same magnitude as that of NSAIDs for their preferential application, in other words, over short-term treatment courses [10]. Therefore, it confirms that glucosamine sulfate may be an appropriate agent for the long-term management of knee osteoarthritis.

**Table 3. Effect size of glucosamine sulfate versus placebo on WOMAC pain and function.**

Outcome	GS effect size (95% CI)	Ref.
<b>WOMAC pain</b>		
Reginster	0.27 (0.002–0.54)	[48]
Pavelka	0.30 (0.03–0.58)	[48]
Two studies pooled	0.27 (0.08–0.46)	
<b>WOMAC function</b>		
Reginster	0.32 (0.05–0.59)	[47]
Pavelka	0.32 (0.04–0.60)	[48]
Two studies pooled	0.31 (0.11–0.50)	

Effects are calculated after 3 years in long-term trials of Reginster [47] and Pavelka [48]. Effect sizes have been calculated with their 95% CI according to the standard method with bias correction by Hedges (1985), as the difference between the mean change from baseline for the verum and placebo groups, divided by the pooled SD. Results are presented separately for the two studies and, after standardizing the results on a 0–100 mm VAS, for the two studies pooled.

CI: Confidence interval; GS: Glucosamine sulfate; OA: Osteoarthritis; SD: Standard deviation; VAS: Visual analog scale; WOMAC: Western Ontario and Macmaster OA index.

To date, no demographic characteristics have been identified that enable the prediction of which patients will benefit from the administration of glucosamine sulfate. From a clinical point of view, effective symptom modification can be observed in patients with different baseline severity, ranging from mild-to-moderate symptoms in the long-term trials [47,48] to moderate-to-severe in shorter studies [43–45]. On the other hand, the subgroup analysis of the GAIT study, with all limitations deriving from the use of glucosamine hydrochloride at a low unit dose, suggests potentially higher efficacy in more severe patient subgroups [59].

Subanalyses from the long-term studies by Reginster [47] suggest that symptom modification is achieved irrespective of baseline joint structure damage [63]. Conversely, structure modification appears to be more effective in patients with milder joint changes when treatment is started [64].

#### Clinical studies conducted with other glucosamine formulations

The GAIT study is among the most important trials performed with glucosamine and is the largest [59]. Its negative results have been summarized earlier. Unfortunately, it has been conducted with

glucosamine hydrochloride at the dose of 500 mg three-times daily, specifically with a substance, formulation and dose that are different from those of the prescription glucosamine sulfate used in all latest trials, and whose different pharmacokinetic, and probably pharmacodynamic, patterns have been discussed previously. In addition, the high placebo response and the diverging findings in the disease severity subgroup analysis have raised several questions [60], and an opportunity has probably been lost to clarify some of glucosamine clinical effects in a large and independent trial [62].

GAIT appears at least to confirm that glucosamine hydrochloride given at a dose of 500 mg three-times daily might not be a preferred option, as previously suggested by Houpt [61]. In this latter study, a formulation and dose of glucosamine hydrochloride, similar to that used in GAIT, produced only limited and nonsignificant benefit over placebo on the symptoms of knee osteoarthritis in a relatively small group of 101 patients treated for 8 weeks. Therefore, it is not known if glucosamine hydrochloride is as effective as glucosamine sulfate in the treatment of osteoarthritis [12].

However, three high-quality trials of glucosamine sulfate have been published that were not able to replicate the favorable effects on symptom modification that have been described in the previous sections of this review [65–67]. All these trials used dietary supplement glucosamine sulfate preparations whose purity and stability are not described, since these are not prescription products. In addition, nothing is known about the bioavailability of the active ingredient, glucosamine, relative to the prescription formulation: this would be an essential prerequisite of any generic product, before any comparison can be made with the reference standard. The lack of this information is indeed surprising. Finally, most of the preparations used in these trials fractionated the total daily dose in two or three administrations, and this may further decrease the active ingredient peaks in plasma and other biological fluids that have been demonstrated to be effective *in vitro* [30].

In a 6-month, randomized, double-blind, placebo-controlled study, Hughes and Carr tested a glucosamine sulfate formulation never tested previously (potassium chloride glucosamine sulfate, plus vitamin C, calcium carbonate and manganese) in a small cohort of heterogenous patients with differing knee osteoarthritis severity [65]. Almost 50% of them were taking NSAIDs at

enrolment and were allowed to continue using them during the study, which may also account for the high placebo response and the lack of difference between treatments.

In the study by McAlindon, administration of glucosamine over 12 weeks was not superior to placebo for symptom modification in knee osteoarthritis [66]. The study was entirely conducted over the internet, and the primary aim of the study was to determine the feasibility of such an approach [68]. It is not clear how this primary aim might have interfered with the added evaluation of glucosamine effectiveness, also given the inclusive eligibility criteria, the unbalanced randomization for several baseline characteristics and the lack of direct patient observation, as discussed by the authors [66].

Cibere and colleagues conducted a placebo-controlled discontinuation trial in a small group of 137 current users of glucosamine supplements who had reported at least moderate improvement in knee osteoarthritis pain [67]. There were no differences in the incidence of disease flare between glucosamine and placebo over 6 months after randomization. Although this study design is very interesting, glucosamine sulfate has been described, similarly to other symptomatic slow-acting drugs in osteoarthritis, to produce a carry-over effect on symptoms after both short- [43] and long-term clinical use [55,56], which may confound the assessments in a discontinuation trial. In fact, almost 60% of patients did not relapse during the 6-month observation period in this study. In addition, the baseline characteristics were imbalanced between groups, with an overwhelming majority of male patients and a more severe disease in the glucosamine group. Finally, since patients were required to remain on the dose of glucosamine that they were taking before the study, 35–40% of patients were randomized to a dose of 1000 mg/day or less, while all successful clinical trials have been performed with a dose of 1500 mg of glucosamine sulfate.

Given these limitations in study design and the use of noncharacterized glucosamine preparations, it is not clear how this clinical trial experience should be considered in the assessment of glucosamine efficacy in osteoarthritis. As a minimum and in agreement with the findings of the Cochrane Review, it is suggested that there may be differences in efficacy between the prescription formulation of

crystalline glucosamine sulfate and dietary supplement glucosamine preparations. Safety was good in all these clinical studies.

### Safety & postmarketing surveillance

All studies and meta-analyses have recognized the good overall safety profile of glucosamine sulfate and of glucosamine in general. Table 4 reports the proportion of patients with adverse events in the most important short-term clinical trials and in pivotal long-term trials of crystalline glucosamine sulfate (with the exclusion of the GUIDE study, whose complete results are currently unpublished). Withdrawals due to adverse events, lack of efficacy or other reasons are also reported. There were never statistically or clinically significant differences between glucosamine sulfate and placebo in the incidence of adverse events or of safety-related withdrawals. On the other hand, in comparative trials, the incidence of adverse events and related withdrawals was always significantly higher in the reference groups receiving conventional NSAIDs than in the glucosamine sulfate group, with the majority of adverse events in the NSAID-treated patients being obviously referred to the gastrointestinal tract.

Although at a significantly lower incidence than with conventional NSAIDs, the low proportion of adverse events with glucosamine sulfate are related to the gastrointestinal system and consist of mild and transient abdominal pain, nausea, dyspepsia, diarrhea or constipation. Headache, drowsiness and fatigue have also been reported. Uncommon adverse events are represented by depressed mood, vertigo and skin rash. With regard to the latter, cross-reactions in patients with seafood allergy are unlikely, due to the purification process that excludes the presence of protein residues in the starting material of sea origin.

Overall, the incidence of these adverse events taken together is lower than 15% in the principal short-term studies, as shown in Table 3. In the pivotal trials of Reginster and colleagues [47] and Pavelka and colleagues [48], the long-term exposure implies a higher incidence of adverse events, which is nevertheless identical to that of placebo and has the same pattern as that summarized above. In these long-term studies, musculoskeletal events were also reported, but they are probably related to the primary rheumatic condition. Cardiovascular events were also common in this elderly population, but they were not related to the study medication and major events occurred with an incidence similar to placebo [69].

**Table 4. Proportion of patients with adverse events and of withdrawals from crystalline glucosamine sulfate high-quality trials of different treatment duration (see Table 1).**

Study	Groups	Patients with adverse events (%)	Patients withdrawn due to			Ref.
			Adverse events (%)	Lack of efficacy (%)	Other reasons (%)	
Noack	Placebo (n = 126)	10.3	6.3	0.0	1.6	[44]
	GS (n = 126)	6.3	4.0	0.0	2.4	
p-value GS versus placebo		NS	NS	-	-	
Müller-Fassbender	Ibuprofen (n = 99)	35.4	7.1	1.0	4.0	[45]
	GS (n = 100)	6.0	1.0	1.0	0.0	
p-value GS versus ibuprofen		<0.001	0.035	-	-	
Rovati	Placebo (n = 77)	24.7	5.2	7.8	10.4	[43]
	GS (n = 79)	15.2	0.0	1.3	1.3	
	Piroxicam (n = 86)	41.9	20.9	3.5	8.1	
	Combination* (n = 77)	36.4	2.6	0.0	3.9	
p-value GS versus placebo		NS	NS	-	-	
p-value GS versus piroxicam		<0.001	<0.001	-	-	
p-value GS versus combination		0.003	NS	-	-	
p-value piroxicam versus combination		NS	0.003	-	-	
Reginster	Placebo (n = 106)	93	17.0	4.7	11.3	[47]
	GS (n = 106)	94	19.8	2.8	13.2	
p-value GS versus placebo		NS	NS	-	-	
Pavelka	Placebo (n = 101)	64	9.9	5.0	30.7	[48]
	GS (n = 101)	66	7.9	7.9	18.8	
p-value GS versus placebo		NS	NS	-	-	

Statistical analysis by the two-tailed  $\chi^2$  or Fisher exact tests, as appropriate.

\*Combination of GS plus piroxicam.

GS: Glucosamine sulfate; NS: Not significant.

Glucosamine is an amino monosaccharide that can enter the hexosamine pathway (one of the alternative routes of glucose metabolism) and thereby increases insulin resistance, as suggested by animal experimental studies using suprapharmacological intravenous doses of the compound [70]. Although this remains an area of attention, human studies with extremely high intravenous [71] or even intra-arterial [72] glucosamine doses indicated that such a mechanism is probably not operating in humans, where insulin sensitivity, secretion or action were not affected. More recently, a study in healthy volunteers with oral repeated doses of a glucosamine sulfate formulation at 1500 mg daily, demonstrated no changes in serum insulin or blood glucose levels with 3-h glucose tolerance test [73]. Another placebo-controlled study showed that patients with Type 2 diabetes receiving a glucosamine and chondroitin sulfate combination for 3 months had no change in

their diabetes management, or in hemoglobin A1c concentrations [74]. Finally, fasting plasma glucose levels were not modified in former short-term studies with crystalline glucosamine sulfate, as well as in the long-term trial by Reginster [75], while in the 3-year study by Pavelka, four patients developed diabetes during the study, but three were on placebo and only one on glucosamine sulfate [48]. Other laboratory evaluations never detected significant abnormalities in hematological or other metabolic parameters.

Interactions with other drugs are unlikely, since glucosamine is mainly absorbed via glucose transporters and does not compete for general absorption mechanisms; in addition, it is mainly metabolized independently of the cytochrome P450 enzyme system [76].

Since crystalline glucosamine sulfate is a prescription drug in several countries of the world, it is subject to strict postmarketing surveillance

analysis. The latest Periodic Safety Update Report estimates an exposure of over 14 million patients in the period 1995–2005, with few adverse drug reaction reports that do not modify the good safety pattern described above.

### Regulatory affairs

Crystalline glucosamine sulfate is approved as a medicinal product, generally as a prescription drug, for the treatment of osteoarthritis or the symptoms of osteoarthritis in 22 countries of the European Union and in several countries of Eastern Europe, Asia and Latin America, totalling 56 countries.

Based on the results of clinical trials, the most widely approved dosing regimen of the prescription medication is 1500 mg glucosamine sulfate once daily, given as an oral soluble powder of crystalline glucosamine sulfate. In some countries, glucosamine-based medicinal products are available over-the-counter in variable regimens, often as solid oral formulations of other glucosamine salts (e.g., hydrochloride).

In the USA, glucosamine-containing products are considered dietary supplements because of the provisions of the Dietary Supplement Health and Education Act of 1994 [77]. This favored the appearance on the market of different glucosamine products, which are not subject to any pharmaceutical control by the US FDA and the authorities of the countries that adopted a similar approach. In fact, the active ingredient content of several of these products has recently been questioned [78]. Whether this had an impact on the disappointing results of some recent clinical trials using these formulations [65–67], together with their problematic study design described above, is unknown. In other trials, where pharmaceutical grade of the dietary supplement formulation used was assured, such as in the NIH GAIT study [59], other factors described above, such as the use of previously undocumented glucosamine salts (i.e., hydrochloride), at different dose regimens and with consequent differences in pharmacokinetic and pharmacological behavior, may have played a role.

### Conclusion

Crystalline glucosamine sulfate is a specific symptom-modifying drug in osteoarthritis for both short- and long-term treatment courses, whose use is largely supported by different high-quality clinical trials. Two 3-year trials also suggested that the drug has joint structure-modifying properties and therefore might be a disease-modifying agent

and among the first-choice medications for the management of osteoarthritis. Actually, long-term follow-up of patients participating in the 3-year trials hypothesized that previous treatment with glucosamine sulfate might prevent patients' disability and recourse to joint surgery, particularly total knee replacement.

The clinical evidence for efficacy and safety has been the object of rigorous systematic reviews and meta-analyses, and resulted in the inclusion of the drug in currently available practice guidelines. While the ACR recommendations date back to the year 2000 [6], in other words, prior to the most intriguing new evidence, and classify the compound among the experimental agents, the EULAR guidelines for knee osteoarthritis [7] attribute to glucosamine sulfate the highest level of evidence, 1A, and the highest strength of recommendation, A, for the management of disease symptoms, along with only six out of the 34 pharmacological and non-pharmacological treatment modalities considered [7]. Conversely, the evidence at the level of the hip is still scanty [8].

The pharmacological events that support the clinical effects of glucosamine sulfate in osteoarthritis appear to be related to the inhibition of the IL-1 intracellular signaling pathway and, thus, of cytokine-induced gene expression. These pharmacological effects are achieved *in vitro* at drug concentrations found in plasma and synovial fluid of knee osteoarthritis patients after oral administration of the standard therapeutic doses. Differences in the clinical effects with generic or dietary supplement glucosamine hydrochloride formulations may indeed be related to differences in dose regimens and in pharmacokinetics, which may lead to differences in the pharmacological properties. In addition, the presence of sulfates in the prescription drug formulation, which is stabilized according to a patented process, has also been suggested to be important from the point of view of favoring some of the compound pharmacometabolic characteristics, which might not be shared by glucosamine hydrochloride. Conversely, preparations of glucosamine sulfate, other than the prescription formulation, manifest differences in quality and dose regimens that would require appropriate pharmacokinetic and bioequivalence assessment [78]. Since this is not currently available, it is impossible to apply the efficacy and safety results obtained with crystalline glucosamine sulfate to these other preparations and *vice versa*, as already noted in the recent Cochrane review [12].

### Future perspective

Glucosamine sulfate is the first pharmacological agent for which a combined symptom- and structure-modifying effect has been demonstrated in appropriate long-term clinical trials. While this evidence is still unique within the treatment of osteoarthritis, future studies of new drugs should take into account this experience and the evolving technology in outcome measurement and clinical trial performances.

Symptoms of the disease will need to be assessed over appropriate treatment durations, in other words, for at least 6 months and for the duration necessary to evaluate joint structure changes, if any. The clinical relevance of the symptom change should be determined based on appropriate patient-reported outcomes.

To date, joint structure-modifying activity has been evaluated mainly by plain radiography, quantitatively monitoring joint space narrowing as a surrogate for cartilage loss and adopting a qualitative assessment for bone reactive changes. More recent radiographic techniques are emerging to assess these outcomes with more accuracy and precision, and must be adopted in clinical trials after their validation is completed. In the meantime, other imaging techniques may prove more powerful in detecting cartilage quantitative and qualitative changes, as well as the modifications in other joint structures and tissues: the best candidate technique in this respect is magnetic resonance imaging.

Whichever technique is employed, changes in joint structure should be clinically relevant in terms of their association with favorable symptom outcomes or by modifying the natural history of the disease. In addition, long-term trial outcomes should focus on parameters of patient's disability, quality of life and disease management. The latter should prospectively assess a possible decrease in the recourse to surgical total joint replacement, once this evaluation can be standardized, and focus on appropriate pharmacoeconomic evaluations.

Besides the general remarks above, future studies of glucosamine sulfate might explore the effects of the substance when administered by the parenteral route, either systemically (e.g., by the intramuscular route), or locally (i.e., intra-articularly), despite the good oral bioavailability reviewed here. In addition, the potential of combination therapy with other drugs, either symptomatic medications or potential disease-modifying agents, deserves further attention.

Finally, glucosamine sulfate has been studied mainly in clinical trials of primary osteoarthritis. Anecdotal evidence of efficacy in secondary osteoarthritis, including post-traumatic disease or sport injury and rehabilitation, has been reported and would require confirmation in appropriately designed studies. Given its putative mechanism of action, the potential of the compound in the prevention of osteoarthritis might also be investigated.

## Executive summary

### Chemistry

- Crystalline glucosamine sulfate is the stabilized form of glucosamine sulfate, specifically, the glucosamine salt used as a prescription drug in osteoarthritis.
- Glucosamine, sulfate, chloride and sodium ions are present in stoichiometric ratios of 2:1:2:2.
- Other glucosamine salts (e.g., hydrochloride) and substances are widely used as dietary supplements, and may not share the same properties.

### Mechanisms of action

- Different *in vitro* studies demonstrated that glucosamine sulfate has both anabolic properties (stimulating the synthesis of proteoglycans) and anticatabolic activities (inhibiting the effects of enzymes, such as metalloproteases).
- However, the mere incorporation of the aminosugar in glucosaminoglycans and stimulation of their synthesis as a simple building block is unlikely, due to the high concentrations required.
- The substance mechanism of action appears to be rather due to glucosamine-induced reversal of the pro-inflammatory and joint-degenerating effects of interleukin (IL)-1.
- This effect is probably accomplished by inhibition of the cytokine intracellular signaling pathway, namely of the activation of nuclear factor (NF)- $\kappa$ B.
- Indeed, glucosamine sulfate inhibits IL-1-stimulated gene expression of cyclooxygenase (COX)-2, inducible nitric oxide synthase (iNOS), cytokines and metalloproteases at glucosamine concentrations found in human plasma (10  $\mu$ M) and synovial fluid after administration of glucosamine sulfate at standard oral doses.
- Sulfate may contribute to the mechanism of action of glucosamine sulfate, overcoming a possible deficiency in inorganic sulfur in the elderly. This provides an additional mechanism compared with other glucosamine salts (e.g., hydrochloride), besides a possibly different pharmacokinetic behavior.

**Executive summary****Pharmacokinetic properties**

- Following oral administration of crystalline glucosamine sulfate 1500 mg once daily in humans, peak plasma concentrations of approximately 10 µM glucosamine are achieved after 3 h on average.
- Similar levels are achieved in the synovial fluid of knee osteoarthritis patients.
- The terminal elimination half-life from human plasma is approximately 15 h.
- Glucosamine absolute bioavailability from crystalline glucosamine sulfate is estimated to be approximately 25% from animal data.
- Glucosamine hydrochloride provides glucosamine peak plasma levels in humans that are threefold lower than 1500 mg once-daily glucosamine sulfate and may be less pharmacologically effective.
- Glucosamine is metabolized independently of the cytochrome P450 system.

**Clinical efficacy**

- The efficacy of crystalline glucosamine sulfate in the short-term (4–12 weeks) control of osteoarthritis symptoms versus placebo, of at least comparable magnitude to conventional nonsteroidal anti-inflammatory drugs (NSAIDs) and with a long-lasting effect after drug withdrawal, has been shown in different clinical studies, including three principal trials in patients with moderate-to-severe symptoms.
- Three pivotal, placebo-controlled trials demonstrated a statistically significant and clinically relevant symptom-modifying effect for treatments ranging from 6 months to 3 years in knee osteoarthritis patients with mild-to-moderate disease.
- The two pivotal, long-term, 3-year trials demonstrated a joint structure-modifying effect based on radiological joint space narrowing.
- In the pivotal 6-month trial (Glucosamine Unum In Die (once-a-day) Efficacy study [GUIDE]), a comparator group receiving the currently preferred symptomatic medication acetaminophen failed to reach a significant benefit versus placebo, differently from glucosamine sulfate.
- In the 6-month, NIH-sponsored Glucosamine/Chondroitin Arthritis Intervention Trial, glucosamine hydrochloride 500 mg three-times daily failed to demonstrate the same efficacy of glucosamine sulfate 1500 mg once daily in GUIDE and in other previous trials, thereby highlighting possible differences in pharmacokinetic and pharmacological behavior.
- Similarly, studies performed with dietary supplement glucosamine sulfate preparations did not demonstrate the same efficacy of the prescription product.

**Safety & tolerability**

- In all clinical trials, glucosamine sulfate had an incidence of adverse events and related withdrawals similar to placebo.
- In comparative trials, safety was significantly better than that of conventional NSAIDs.
- The low proportion of adverse events consists mainly of mild and transient episodes of abdominal pain, nausea, dyspepsia, diarrhea, constipation, headache, drowsiness and fatigue. Uncommon adverse events are represented by depressed mood, vertigo and skin rash.
- Cross-reactions in patients with seafood allergy are unlikely, owing to the purification process that eliminates protein residues in the starting material of sea origin.
- Human studies failed to demonstrate an effect on glucose metabolism, although this remains an area of attention due to the possible interaction with the hexosamine pathway.
- Glucosamine sulfate is not expected to interact with other drugs (with rare exceptions), as it does not interfere with general absorption mechanisms and is not metabolized by the cytochrome P450 system.

**Dosage & administration**

- The most widely studied and approved prescription formulation is available as sachets of oral soluble powder of crystalline glucosamine sulfate, equivalent to 1500 mg glucosamine sulfate, to be administered once daily.

**Bibliography**

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

1. Felson DT, Lawrence RC, Dieppe PA *et al.*: Osteoarthritis: new insights. Part 1, the disease and its risk factors. *Ann. Intern. Med.* 133, 635–646 (2000).
2. Pendleton A, Arden N, Dougados M *et al.*: EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). *Ann. Rheum. Dis.* 59, 936–944 (2000).
3. Felson DT, Zhang Y: An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. *Arthritis Rheum.* 41, 1343–1355 (1998).
4. Oliveira SA, Felson DT, Reed JI, Cirillo PA, Walker AM: Incidence of symptomatic hand, hip and knee osteoarthritis among patients in a health maintenance organisation. *Arthritis Rheum.* 38, 1134–1141 (1995).
5. Guccione AA, Felson DT, Anderson JJ *et al.*: The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. *Am. J. Public Health* 84, 351–358 (1994).
6. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. *Arthritis Rheum.* 43, 1905–1915 (2000).
7. Jordan KM, Arden NK, Doherty M *et al.*: EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). *Ann. Rheum. Dis.* 62, 1145–1155 (2003).

- **Practice guidelines including most of the trials performed in osteoarthritis, specifically at the knee joint, which are therefore evidence-based.**

8. Zhang W, Doherty M, Arden N *et al.*: EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCI-SIT). *Ann. Rheum. Dis.* 64, 669–681 (2005).
9. Towheed TE, Maxwell L, Judd MG *et al.*: Acetaminophen for osteoarthritis. The Cochrane Database of Systematic Reviews. Issue 1. Art. No.:CD004257.pub2. DOI: 10.1002/14651858. (2006).
10. Bjordal JM, Ljunggren AE, Klovning A, Slørdal L: Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritis knee pain: meta-analysis of randomised placebo controlled trials. *Br. Med. J.* 329, 1317–1322 (2004).
11. Hamerman D: The biology of osteoarthritis. *N. Engl. J. Med.* 320, 1322–1330 (1989).
12. Towheed TE, Maxwell L, Anastassiades TP *et al.*: Glucosamine therapy for treating osteoarthritis. The Cochrane Database of Systematic Reviews, Issue 2. Art. No.:CD002946.pub2.DOI: 10.1002/14651858 (2005).
- **Cochrane review that assesses most of the glucosamine clinical trials until 2004.**
13. De Wan M, Volpi G: A method of preparing mixed glucosamine salts. US patent 5,847,107. (1997).
14. Noyszewski EA, Wroblewski K, Dodge GR *et al.*: Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfate in articular cartilage explants. *Arthritis Rheum.* 44, 1089–1095 (2001).
15. Bassleer C, Rovati LC, Franchimont P: Glucosamine sulfate stimulates proteoglycan production in human chondrocytes *in vitro*. *Osteoarthr. Cartil.* 6, 427–434 (1998).
16. Piperno M, Reboul P, Helio Le Graverand MP *et al.*: Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes *in vitro*. *Osteoarthr. Cartil.* 8, 207–212 (2000).
17. Dodge GR, Jimenez SA: Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritic articular chondrocytes. *Osteoarthr. Cartil.* 11, 424–432 (2003).
18. Sandy JD, Gamett D, Thompson V, Verscharen C: Chondrocyte-mediated catabolism of aggrecan: aggreganase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. *Biochem. J.* 335, 59–66 (1998).
19. Altman RD, Cheung H: Glucosamine sulfate on cartilage: lapine study. *Arthritis Rheum.* 44 (Suppl. 9), 1535 (2001).
20. Tiraloche G, Girard C, Chouinard L *et al.*: Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. *Arthritis Rheum.* 52, 1118–1128 (2005).
21. Mroz PJ, Silbert JE: Use of <sup>3</sup>H-glucosamine and <sup>35</sup>S-sulfate with cultured human chondrocytes to determine the effect of glucosamine concentration on formation of chondroitin sulfate. *Arthritis Rheum.* 50, 3574–3579 (2004).
22. Biggee BA, Blinn CM, McAlindon TE, Nuite M, Silbert JE: Low levels of human serum glucosamine after ingestion of glucosamine sulfate relative to capability for peripheral effectiveness. *Ann. Rheum. Dis.* 65, 222–226 (2006).
23. Setnikar I, Rovati LC: Absorption, distribution, metabolism and excretion of glucosamine sulfate: a review. *Arzneimittelforschung* 51, 699–725 (2001).
24. Laverty S, Sandy JD, Celeste C *et al.*: Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. *Arthritis Rheum.* 52, 181–191 (2005).
25. Gouze JN, Bordji K, Gulberti S *et al.*: Interleukin-1 $\beta$  down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1 $\beta$ -mediated effects in rat chondrocytes. *Arthritis Rheum.* 44, 351–360 (2001).
26. Shikhman AR, Kuhn K, Alaaeddine N, Lotz M: N-acetylglucosamine prevents IL-1 $\beta$ -mediated activation of human chondrocytes. *J. Immunol.* 166, 5155–5160 (2001).
27. Gouze JN, Bianchi A, Becuwe P *et al.*: Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF- $\kappa$ B pathway. *FEBS Lett.* 510, 166–170 (2002).
28. Largo R, Alvarez-Soria MA, Diez-Ortego I *et al.*: Glucosamine inhibits IL-1 $\beta$ -induced NF $\kappa$ B activation in human osteoarthritic chondrocytes. *Osteoarthr. Cartil.* 11, 290–298.
- **Describes the most probable action mechanism of glucosamine sulfate in osteoarthritis.**
29. Alvarez-Soria MA, Largo R, Calvo E, Egado J, Herrero-Beaumont G: Differential anticatabolic profile of glucosamine sulfate versus other anti-osteoarthritic drugs on human osteoarthritic chondrocytes and synovial fibroblast in culture. *Osteoarthr. Cartil.* 13(Suppl. A), P309 (2005).
30. Piepoli T, Zanelli T, Letari O *et al.*: Glucosamine sulfate inhibits IL-1 $\beta$ -stimulated gene expression at concentrations found in humans after oral intake. *Arthritis Rheum.* 52(Suppl. 9), 1326 (2005).
- **Indicates that glucosamine is effective *in vitro* on the putative mechanism of action, at the concentrations found in human plasma and synovial fluid.**
31. Uitterlinden EJ, Jahr H, Koevoet JLM *et al.*: Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. *Osteoarthr. Cartil.* 14, 250–257 (2006).
32. Hoffer LJ, Kaplan LN, Hamadeh MJ, Grigoriu AC, Baron M: Sulfate could mediate the therapeutic effect of glucosamine sulfate. *Metabolism* 50, 767–770 (2001).
- **Possible contribution of sulfates in the pharmacological effects of glucosamine sulphate.**
33. Cordoba F, Nimni ME: Chondroitin sulfate and other sulfate containing chondroprotective agents may exhibit their effects by overcoming a deficiency of sulfur amino acids. *Osteoarthr. Cartil.* 11, 228–230 (2003).
34. Aghazadeh-Habashi A, Settari S, Pasutto FM, Jamali F: Single dose pharmacokinetics and bioavailability of glucosamine in the rat. *J. Pharm. Pharmacol. Sci.* 5, 181–184 (2002).
35. Adebowale A, Du J, Liang Z, Leslie JL, Eddington ND: The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. *Biopharm. Drug Dispos.* 23, 217–235 (2002).
36. Du J, White N, Eddington ND: The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. *Biopharm. Drug Dispos.* 25, 109–116 (2004).
37. Persiani S, Roda E, Rovati LC *et al.*: Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. *Osteoarthritis Cartilage* 13, 1041–1049 (2005).
- **First full description of the pharmacokinetics of glucosamine sulfate in man.**
38. Persiani S, Locatelli M, Fiorentino S, Rovati LC, Roda A: Absolute bioavailability of glucosamine after administration of crystalline glucosamine sulfate in rats. *Osteoarthr. Cartil.* 13(Suppl. A), P161 (2005).



39. Persiani S, Rotini R, Trisolino G *et al.*: Glucosamine plasma and synovial fluid concentrations before and after oral administration of crystalline glucosamine sulfate in knee osteoarthritis patients. *Arthritis Rheum.* 52(Suppl. 9), 1342 (2005).
40. Jackson CG, Plaas AH, Barnhill JG, Harris CL, Clegg DO: The pharmacokinetics of oral glucosamine and chondroitin sulfate in humans. American College of Rheumatology meeting late breaking (2005) (Abstract L13).
41. McAlindon TE, La Valley MP, Gulin JP, Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. *JAMA* 283, 1469–1475 (2000).
42. Richy F, Bruyere O, Ethgen O *et al.*: Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. A comprehensive meta-analysis. *Arch. Int. Med.* 163, 1514–1522 (2003).
43. Rovati LC: The clinical profile of glucosamine sulfate as a selective symptom modifying drug in osteoarthritis: current data and perspectives. *Osteoarthr. Cartil.* 5(Suppl. A), 72 (1997).
- **Clinical trial that reflects most of the results of previous studies of glucosamine sulfate for short-term symptom modification.**
44. Noack W, Fischer M, Förster KK, Rovati LC, Setnikar I: Glucosamine sulfate in osteoarthritis of the knee. *Osteoarthr. Cartil.* 2, 51–59 (1994).
45. Müller-Fassbender H, Bach GL, Haase W, Rovati LC, Setnikar I: Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. *Osteoarthr. Cartil.* 2, 61–69 (1994).
46. Committee for Proprietary Medicinal Products: Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis (CPMP/EWP/784/97). The European Agency for the Evaluation of Medicinal Products. London, UK (1998).
47. Reginster JY, Deroisy R, Rovati LC *et al.*: Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. *Lancet* 357, 251–256 (2001).
- **Pivotal 3-year clinical trial demonstrating symptom and structure modification for glucosamine sulfate in knee osteoarthritis.**
48. Pavelka K, Gatterova J, Olejarova M *et al.*: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. *Arch. Intern. Med.* 162, 2113–2123 (2002).
- **Pivotal confirmatory 3-year trial, replicating the results of Reginster and colleagues [47].**
49. Bruyere O, Pavelka K, Rovati LC *et al.*: Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. *Menopause* 11, 138–143 (2004).
50. Brandt KD, Mazzuca SA, Conrozier T *et al.*: Which is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with knee osteoarthritis? *J. Rheumatol.* 29, 1308–1320 (2002).
51. Pavelka K, Bruyere O, Rovati LC *et al.*: Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. *Osteoarthr. Cartil.* 11, 730–737 (2003).
- **Demonstrates that pain relief by glucosamine sulfate did not confound the assessment of the compound structure-modifying effect identified in the trials of Reginster and Pavelka [47,48].**
52. McAlindon T: Glucosamine for osteoarthritis: dawn of a new era? *Lancet* 357, 247–248 (2001).
53. Brandt KD, Mazzuca SA: Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs. *Arthritis Rheum.* 52, 3349–3359 (2005).
54. Bruyere O, Reginster JY, Giacobelli G, Barbetta B, Rovati LC, Pavelka K: Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate. *Arthritis Rheum.* 54(7), 2339–2341 (Epub ahead of print).
55. Bruyere O, Compere S, Rovati LC *et al.*: Five-year follow-up of patients from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis. *Arthritis Rheum.* 48(Suppl. 9), 89 (2003).
56. Pavelka K, Gatterova J, Giacobelli G, Olejarova M, Rovati LC: Glucosamine sulfate prevents total joint replacement in the long-term follow-up of knee osteoarthritis patients. *Arthritis Rheum.* 50(Suppl. 9), 251 (2004).
57. Altman MD, Abadie MD, Avouac MD *et al.*: Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. *Osteoarthr. Cartil.* 13, 13–19 (2005).
- **Position paper on the use of total joint replacement as an outcome in osteoarthritis clinical trials, summarizing some of the data of the two abstracts above that suggest that glucosamine sulfate might reduce the incidence of joint surgery.**
58. Herrero-Beaumont G, Román JA, Trabado MC *et al.*: Effects of glucosamine sulfate on 6-month control of knee osteoarthritis symptoms vs. placebo and acetaminophen: results from the Glucosamine Unum In Die Efficacy (GUIDE) trial. *Arthritis Rheum.* 52 (Suppl. 9), 1203 (2005).
- **New pivotal trial of glucosamine sulfate for symptom modification in knee osteoarthritis.**
59. Clegg DO, Reda DJ, Harris CL *et al.*: Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *N. Engl. J. Med.* 358, 795–808 (2006).
- **NIH-sponsored trial of glucosamine hydrochloride, which failed to demonstrate the same benefit on symptoms of trials of glucosamine sulphate.**
60. Clegg DO, Reda DJ, Harris CL *et al.*: Glucosamine and chondroitin sulfate for knee osteoarthritis. *N. Engl. J. Med.* 354, 2184–2185 (2006).
61. Houpt JB, McMillan R, Wein C, Paget-Dellio SD: Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. *J. Rheumatol.* 26, 2423–2430 (1999).
62. Hochberg MC: Nutritional supplements for knee osteoarthritis – still no resolution. *N. Engl. J. Med.* 354, 858–860 (2006).
63. Bruyere O, Honore A, Rovati LC *et al.*: Radiologic features poorly predict clinical outcomes in knee osteoarthritis. *Scand. J. Rheumatol.* 31, 13–16 (2002).
64. Bruyere O, Honore A, Ethgen O *et al.*: Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. *Osteoarthr. Cartil.* 11, 1–5 (2003).
65. Hughes R, Carr A: A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. *Rheumatology* 41, 279–284 (2002).

66. McAlindon T, Formica M, LaValley M, Lehmer M, Kabbara K: Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomised double-blind controlled trial. *Am. J. Med.* 117, 643–649 (2004).
67. Cibere J, Kopec JA, Thorne A *et al.*: Randomised, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. *Arthritis Care Res.* 51, 738–45 (2004).
68. McAlindon T, Formica M, Kabbara K, LaValley M, Lehmer M: Conducting clinical trials over the internet: feasibility study. *Br. Med. J.* 327, 484–487 (2003).
69. Reginster J-Y, Rovati LC, Henrotin Y *et al.*: Glucosamine sulphate and osteoarthritis. *Lancet* 357, 1618 (2001).
70. Baron AD, Zhu JS, Zhu JH *et al.*: Glucosamine induces insulin resistance *in vivo* by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. *J. Clin. Invest.* 96, 2792–2801 (1995).
71. Monauni T, Zenti MG, Cretti A *et al.*: Effects of glucosamine infusion on insulin secretion and insulin action in humans. *Diabetes* 49, 926–935 (2000).
72. Pouwels MJ, Jacobs JR, Span PN *et al.*: Short-term glucosamine infusion does not affect insulin sensitivity in humans. *J. Clin. Endocrinol. Metab.* 86, 2099–2103 (2001).
73. Tannis AJ, Barban J, Conquer JA: Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. *Osteoarthr. Cartil.* 12, 506–511 (2004).
74. Scroggie DA, Albright A, Harris M: The effect of Glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with Type 2 diabetes mellitus. A placebo-controlled, double-blinded, randomized clinical trial. *Arch. Int. Med.* 163, 1587–1590 (2003).
75. Rovati LC, Annefeld M, Giacovelli G, Schmid K, Setnikar I: Glucosamine in osteoarthritis. *Lancet* 354, 1640, author reply 1641–1642 (1999).
76. Anderson JW, Nicolosi RJ, Borzelleca JF: Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. *Food Chem. Toxicol.* 43, 187–201 (2005).
77. Dietary Supplement Health and Education Act of 1994, Pub: L. No. 103–417, 103rd Congress, October 25 (1994)
78. Russell AS, Aghazadeh-Habashi A, Jamali F: Active ingredient consistency of commercially available glucosamine sulfate products. *J. Rheumatol.* 29, 2407–2409 (2002).

**Affiliations**

- Gabriel Herrero-Beaumont, MD  
Autonomous University of Madrid,  
Rheumatology Department, Fundación Jiménez  
Díaz-Capio, Avenida Reyes Católicos 2, 28040  
Madrid, Spain  
Tel.: +34 915 504 918;  
Fax: +34 915 494 764;  
gherrero@fjd.es
- Lucio C Rovati, MD  
Clinical Pharmacology Department,  
Rottapharm, Monza, Italy  
Tel.: +39 039 739 0318;  
Fax: +39 039 739 0371;  
lucio.rovati@rotta.com